HeartFlow has announced that it and Longview Acquisition Corporation have mutually agreed to terminate their previously announced business combination agreement as a result of current unfavourable market conditions.
The merger had first been announced in July 2021, and once completed, would have seen the combined company operate as HeartFlow Group and listed on the New York Stock Exchange.
HeartFlow’s core product, the HeartFlow FFRCT Analysis, is a non-invasive cardiac test for stable symptomatic patients with coronary artery disease (CAD). Using a standard coronary computed tomography angiogram (CTA), the HeartFlow Analysis creates a digital, personalised 3D model of the heart and provides CTA-derived fractional flow reserve (FFRCT) values along the coronary arteries. The HeartFlow Analysis has regulatory clearance and is commercially available in the USA, the European Union, the UK and Japan.
Longview Acquisition Corp is a special purpose acquisition company sponsored by affiliates of Glenview Capital Management.